Creso Pharma set to expand human health product line with technological breakthrough
Creso Pharma has achieved a key technological milestone, developing its first water-soluble microgranulated hemp plant granules product as an expansion of its cannaQIX® human health product line.
The news comes directly after the company announced it had sold over 2.5 million cannaQIX® lozenges (the equivalent of 100,000 pack sold) since the human health product’s launch in April 2018.
Today’s announcement marks a further milestone in the growth of Creso’s human health product line.
The new technology has been developed over the past nine months in conjunction with Switzerland’s Domaco Pharma and allows hemp oil-free manufacturing of cannaQIX® hemp plant-based gum arabicum lozenges, Creso Pharma’s hemp and vitamin-based food supplement.
This development is significant for several reasons.
Firstly, as stated, the technological breakthrough will be used to extend Creso’s successful cannaQIX® product line.
Secondly, the new technology allows hemp oil free production, bringing the full benefit of the natural hemp plant to consumers.
Furthermore, the product offers significant regulatory advantages in several countries. Importantly, the formulation contains hemp compounds which are already approved for use in consumer products, providing Creso with a path to market for food supplement products without the need for regulatory approval.
“With the achievement of this innovation of the oil free hemp based technology Creso successfully addresses the regulatory and market access challenges enabling us to enter additional markets on a global basis,” said Dr. Gian Trepp, Creso’s R&D/Commercial Director.
As with most Creso products, this new product helps to manage stress and improves well-being in its consumers and comes at a time when there is a growing desire globally for alternative natural stress and pain management products.
The product opens up a range of new territories for Creso.
“The new products contain various hemp compounds which are already approved for use in consumer products,” said Dr. Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma.
“Importantly, this means that we have an additional path to market for our hemp-based food supplements without the need for regulatory approval, thus increasing our commercial options and expanding the potential territories we can sell the products in.”
Creso plans to distribute the new products globally with different commercial partners in several countries and expects that the products will be ready for launch in Q3 2020.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.